Largest Randomized Clinical Trial Of Implantable Cardioverter Defibrillator Recipients Demonstrates Excellent Patient Outcomes With Or Without Defibrillation Testing

[PR Newswire] – NATICK, Mass., May 8, 2014 /PRNewswire/ — A Boston Scientific Corporation (BSX) study demonstrated that outcomes for patients with the company’s transvenous implantable cardioverter defibrillators (ICD) who received routine defibrillatio more

View todays social media effects on BSX

View the latest stocks trending across Twitter. Click to view dashboard

See who Boston is hiring next, click here to view